Neurofibromatosis type 1 (NF1) is a common genetic disorder caused by mutations in the NF1 gene, which encodes neurofibromin, a GTPase-activating protein (GAP)-related domain that negatively regulates the Ras/mitogen-activated protein kinase (RAS/MAPK) signaling pathway. This pathway is critical for cell proliferation and survival, and its dysregulation can lead to various disease manifestations. Although NF1 is widely recognized for its cutaneous features – such as café-au-lait macules, freckling and neurofibroma – it also has significant effects on the vascular system. NF1-associated vasculopathy can affect different vascular beds, resulting in potentially life-threatening complications, including hypertension, aneurysms and ischemic events.
One of the lesser known, but serious, complications of NF1 is cerebral vasculopathy, which is often underrecognized due to its asymptomatic presentation in many patients. This condition is frequently discovered incidentally through imaging performed for other indications. There is some evidence suggesting a higher incidence of cerebrovascular abnormalities in children with optic pathway gliomas; however, whether or not this relationship is causal remains uncertain. Children with NF1-associated optic gliomas undergo more frequent imaging surveillance, which could explain the apparent increased incidence of cerebral vasculopathy since, typically, the findings of cerebral vasculopathy in these situations are asymptomatic.
Frequency of Imaging Impacts Early Detection
The estimated prevalence of cerebral vasculopathy in NF1 ranges from 2.5% to 7.5%, based on data from limited retrospective cohort studies and case series. However, the true incidence remains difficult to determine, as many NF1 patients do not routinely undergo neurovascular imaging. Current guidelines do not recommend routine MRI screening for optic pathway gliomas unless symptomatic, and cerebral vascular imaging generally is not performed unless clinical symptoms arise. The higher frequency of imaging in some children with NF1, often due to optic pathway glioma surveillance, may lead to earlier detection of otherwise asymptomatic vascular changes (Figure 1), contributing to a higher diagnostic rate in these patients.
Figure 1: 10-year-old child with NF1 – enlargement of right optic verve consistent with optic glioma (A), severe stenosis right middle cerebral artery (B), and Moyamoya collateral circulation on digital subtraction angiogram (C).
Understanding the Pathophysiology
The pathophysiology of cerebral vasculopathy in NF1 is not yet fully understood. The NF1 gene produces several isoforms via alternative splicing, and some of these are expressed in vascular tissues. The most well-studied isoform is NF1 Type I, the full-length neurofibromin. This isoform is expressed in multiple tissues, including vascular smooth muscle cells (VSMCs) and endothelial cells. In VSMCs, neurofibromin’s regulation of Ras signaling plays a key role in controlling cell growth and migration. Dysregulation of neurofibromin contributes to the development of cerebral vasculopathy, including arterial stenosis, occlusion and progressive vasculopathies such as Moyamoya syndrome in NF1 patients. In endothelial cells, neurofibromin is essential for maintaining cell survival, migration and angiogenesis. A loss of neurofibromin function in these cells can result in endothelial dysfunction, predisposing individuals to abnormal vessel formation and vascular malformations.
Although NF1-associated vasculopathy can involve various parts of the vascular system, the renal, celiac, iliac, abdominal aorta and cerebral vessels are the most frequently affected. The reasons why only certain arteries or groups of arteries are selectively involved remain unclear, and no definitive genotype-phenotype correlation has been established to explain this phenomenon. The most commonly reported cerebral vascular abnormalities in NF1 include focal stenosis (Figure 2), occlusion, Moyamoya syndrome (Figure 3), fusiform dilation, aneurysms and arteriovenous fistulae.
Figure 2: Focal left middle cerebral artery stenosis (red arrow) without compensatory circulation
Figure 3: Moyamoya syndrome in young child with NF1 – Occlusion of right middle cerebral artery with lenticulostriate “moyamoya” collaterals.
Managing the Condition
Several important questions about the nature of NF1-associated cerebral vasculopathy remain unanswered. The natural history, progression and long-term prognosis of this condition are not well understood, leaving gaps in clinical management. As a result, there is no consensus on optimal monitoring, imaging or treatment strategies for cerebral vasculopathy in NF1 patients. This lack of understanding has led to uncertainty in the development of standardized guidelines.
One major area of debate is the role of routine vascular screening in NF1 patients. Given the variable presentation and severity of vasculopathy, particularly in asymptomatic individuals, the necessity, frequency and scope of screening remain controversial. Some experts advocate for regular screening, especially in high-risk groups, while others suggest a more conservative approach to avoid unnecessary interventions and anxiety in patients with low-risk profiles.
Another area of uncertainty is the management of asymptomatic cerebral vasculopathy, such as Moyamoya disease. There is ongoing debate about whether these patients should undergo revascularization surgery or be managed with antiplatelet therapy alone. While surgery has demonstrated benefits in symptomatic patients, improving cerebral perfusion and preventing strokes (Figure 4), the timing and indications for surgical intervention in asymptomatic individuals remain unclear. Some clinicians recommend early surgical intervention to prevent future ischemic events, while others favor a conservative, watchful approach, relying on antiplatelet therapy to reduce stroke risk without the complications associated with surgery, especially as the natural history of asymptomatic Moyamoya in NF1 patients is not well established.
Figure 4: Superficial temporal artery (STA) to middle cerebral artery (MCA) anastomosis in child with symptomatic Moyamoya syndrome from NF1.
The heterogeneity of NF1-associated vasculopathies further complicates management decisions. Moyamoya disease, with its characteristic progressive stenosis of cerebral arteries, may require different treatment strategies compared to other forms of NF1 vasculopathy, such as focal arterial stenosis or aneurysms. This variability underscores the need for more detailed, stratified treatment guidelines tailored to the specific vasculopathy and the patient’s overall risk profile.
Further Research is Needed
The current lack of comprehensive research and clear clinical consensus on monitoring, timing and treatment options for NF1-related cerebral vasculopathy highlights the urgent need for multicenter studies. These studies should aim to identify predictive markers of disease progression, evaluate the efficacy of various treatment approaches, and develop evidence-based guidelines to optimize care and improve long-term outcomes for patients with NF1. Further understanding the distinct roles of the various NF1 isoforms in vascular tissue may also provide future insights into targeted therapies aimed at restoring normal vascular function in NF1 patients.
The management of NF1-related neurovascular complications remains a key area of focus for the multidisciplinary team at Phoenix Children’s neurofibromatosis clinic, a member of the Neurofibromatosis Clinic Network established by the Children’s Tumor Foundation. Our clinic provides care to more than 200 pediatric patients with NF1 each year, addressing the full spectrum of disease manifestations, from benign tumors to serious neurovascular and cardiovascular complications. We are committed to contributing to the advancement of research and clinical care, particularly in the area of cerebral vasculopathy, to improve the quality of life for patients with NF1.
References:
- Ghosh PS, Rothner AD, Emch TM, Friedman NR, Moodley M. Cerebral vasculopathy in children with neurofibromatosis type 1. J Child Neurol. 2013;28:95-101. PMID: 22532547.
- Kaas B, Huisman TA, Tekes A, Bergner A, Blakeley JO, Jordan LC. Spectrum and prevalence of vasculopathy in pediatric neurofibromatosis type 1. J Child Neurol. 2013;28:561-9. PMID: 22832780.
- Barreto-Duarte B, Andrade-Gomes FH, Arriaga MB, Araújo-Pereira M, Cubillos-Angulo JM, Andrade BB. Association between neurofibromatosis type 1 and cerebrovascular diseases in children: A systematic review. PLoS One. 2021;16:e0241096. PMID: 33395412.
- Lehman LL, Ullrich NJ. Cerebral Vasculopathy in Children with Neurofibromatosis Type 1. Cancers (Basel). 2023;15:5111. PMID: 37894478.